NCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 15, 2026 to Dec 1, 2026
- Notable Start date: Sep 15, 2026 to Oct 15, 2026
- Eligibility criteria expanded, about 30 words
- Secondary endpoints: details revised at 1 of 6 entries
- Site details revised
- Notable Recruitment opened
- Start date: Oct 1, 2026 to Sep 15, 2026
- Site details revised
- Notable Eligibility criteria shortened, about 18 wordsv4
- Notable Start date: Jul 1, 2026 to Oct 1, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in ribonucleic acid polymerase II serine levels
Timeframe: Within 72 hours post versus pre-samuraciclib treatment
Secondary (6)
Incidence of samuraciclib-related adverse events
Completion of 14 days of study drug (Feasibility)
Completion of the on-protocol research endoscopic ultrasound/fine needle biopsy (Feasibility)
Adequate biopsy (≥ 3 cores with ≥30% tumor cellularity) (Feasibility)
Time (days) from last dose of study drug to first definitive therapy (surgery or cycle 1 day 1 of neoadjuvant chemotherapy)
Show 1 moreShow less
Incidence of schedule delays attributable to study drug
Arms and interventions
Treatment (Samuraciclib)Experimental
Patients receive samuraciclib PO QD for 14 days on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients will have a research EUS/FNB on study. Patients also undergo CT scans during screening and blood sample collection on study.
Drugs: Samuraciclib
Procedures: Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States